Satellos Bioscience Inc.
MSCL.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 30.22% | 21.10% | 41.02% | 119.20% | 179.80% |
| Gross Profit | -30.22% | -21.10% | -41.02% | -119.20% | -179.80% |
| SG&A Expenses | 18.25% | 7.91% | 1.74% | 21.77% | 62.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.30% | 16.71% | 26.36% | 77.33% | 126.71% |
| Operating Income | -26.30% | -16.71% | -26.36% | -77.33% | -126.71% |
| Income Before Tax | -3.99% | -33.00% | -37.21% | -74.62% | -96.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.53% | -33.56% | -37.61% | -74.62% | -96.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.53% | -33.56% | -37.61% | -74.62% | -96.17% |
| EBIT | -26.30% | -16.71% | -26.36% | -77.33% | -126.71% |
| EBITDA | -26.29% | -16.69% | -26.32% | -77.28% | -126.97% |
| EPS Basic | 24.26% | -9.08% | -13.32% | -33.16% | -2.37% |
| Normalized Basic EPS | 12.49% | 6.49% | 2.05% | -16.48% | -25.28% |
| EPS Diluted | 24.26% | -9.08% | -13.32% | -33.16% | -2.37% |
| Normalized Diluted EPS | 12.49% | 6.49% | 2.05% | -16.48% | -25.28% |
| Average Basic Shares Outstanding | 38.43% | 26.47% | 22.95% | 32.84% | 64.37% |
| Average Diluted Shares Outstanding | 38.43% | 26.47% | 22.95% | 32.84% | 64.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |